News Archives | Future Medicine India


Belantamab gets approval as a fourth-line therapy for multiple myeloma

Belantamab mafodotin (Blenrep) has been recently approved by the US FDA as a fourth-line therapy in treating adult patients with relapsed or refractory multiple myeloma, announced GlaxoSmithKline.

Read More..

Zydus Cadila launches phase 2 trial of its COVID-19 vaccine candidate

Zydus Cadila has launched phase II clinical trials of its COVID-19 vaccine candidate, ZyCoV-D, following its successful results from phase I study where the vaccine was found to be safe and well-tolerated in healthy participants.


NSNIS Patiala, CSS-SRIHER launches courses in sports physiotherapy and sports nutrition

With an effort to ensure that knowledge of sports science is applied to train athletes even at the grassroot level, Netaji Subhas National Institute of Sports (NSNIS), Patiala, has signed a Memorandum of Understanding (MOU) with Center for Sports Science (CSS) of Sri Ramachandra Institute of Higher Education and Research (SRIHER), Chennai, to jointly conduct six- month certificate courses in sports science subjects.


EC gives conditional nod to pretomanid for treating drug-resistant TB

Pretomanid has been granted a conditional marketing authorisation by the European Commission (EC) for treating highly drug-resistant forms of pulmonary tuberculosis (TB).


Young children may be spewing more SARS-CoV-2 than adults, say researchers

Children aged younger than 5 years may carry 10-fold to 100-fold greater amount of SARS-CoV-2 in the upper respiratory tract compared to those aged 5 to 17 years and adults (18 to 65), finds a recent study published in JAMA Pediatrics .


Valve-in-valve TAVR could raise heart failure risk: Study

Valve-in-valve transcatheter aortic valve replacement (AVR) was linked to more heart failure (HF) hospitalisations and permanent pacemaker implantation, according to the study published in the Journal of the American College of Cardiology.


FDA approves cannabidiol for seizures associated with TSC

The US FDA has approved cannabidiol (Epidiolex) for the treatment of seizures associated with tuberous sclerosis complex (TSC) in patients one year of age and older.